

PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
February 27, 2008

Members Present:

Larry Fleming, MD
 Tom Frazier
 Bradley Fedderly, MD
 James Boblin, MD
 Christine Sorkness, PharmD
 Kevin Izard, MD
 Steve Maike, RPh
 Rosanne Barber
 Shel Gros,
 Anthony DeFranco, MD
 Alicia Walker, PharmD

Absent:

Michael Witkovsky, MD
 Ward Brown, MD—Alternate/Specialist
 Tom Hirsch, MD

Staff Present:

Jason Helgerson, Medicaid Director
 Valerie Taylor, PharmD, Provider Synergies
 Mike Mergener, RPh, PhD

Public Testimony

| Name | Company | Drug |
|--------------------|-------------------------|-----------------------|
| Sherry Siegel | King Pharma | Avinza and (Skelaxin) |
| Paul Soveik | BMS | Avapro/Avalide |
| Prakash Shan | Comprehensive CV Care | Coreg CR |
| Eugene Kaji | UW Cardiology | Coreg CR |
| Fran Kaiser | Merck | Zetia |
| Scott Andersen | AstraZeneca | Crestor |
| William Maierhofer | Mayo Clinic | Lipitor |
| G. Subramani | Cardiologist | Statin Class |
| Anthony Rieder | Alcon Labs | Ciprodex Otic |
| Scott Budsberg | UCB Pharma | Keppra |
| George Morris | St Lukes Medical Center | Anticonvulsants |
| Linda Allen | Epilepsy Program | Anticonvulsants |
| Joseph Jares | Epilepsy Society | Anticonvulsants |
| Brenda Dierschke | Bellin Hospital | Lyrica |
| John St. Peter | Takeda Pharmaceuticals | Rozerem and (Actos) |
| Steven Brown | Insomnia Center | Rozerem |

| | | |
|-------------------|---------------------------|--|
| Tina Hisel | Astellas | Vesicare |
| Steven Woods | Shire | Phosphate Binders |
| Donna | Roche | Pegasys |
| Jose Franco | Medical College of WI | Hepatitis C Agents |
| Martin Goliak | Biogen Ibec | Avonex, |
| Lisa Goetz | Procter & Gamble | Asacol |
| Mike Metz | | TZDs |
| Traci Purath | Comprehensive HA Clinic | Antimigraines |
| Beth Vanderheyden | Pfizer | Relpax and (Caduet, Lipitor, Lyrica, Genotropin) |
| Seonyoung Ryu | Amgen | Aranesp |
| Sanja Dragnic | EMDSerono | Saizen |
| Lisa Toy | Children's Hospital of WI | Growth Hormone |
| Thomas Stuart | Lilly | Humatrope |
| Todd Mydler | Schering Plough | Hepatitis C Agents |
| Kyle Kilchrist | Allergan | Sanctura XR |

Jason Helgerson read the script to move the meeting to the closed session.

Since the next part of the meeting is to discuss manufacturer-specific supplemental rebate amounts which needs to be confidential because of the competitive nature of the rebate agreements, I would ask for a motion to go into closed session.

State open meeting law requires that we record how each committee member votes on the motion to go into closed session. Therefore, we will be taking a roll call vote.

Dr Izard made the motion and Dr Fedderly seconded the motion. The roll call vote indicated that all were in favor.

Acne Agents, Topical (Acne)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications |
|---|--------------|--------------------|--------------------|-------------------------|
| erythromycin (topical) | 8.1% | ON | Generic | |
| clindamycin phosphate (topical) | 33.8% | ON | Generic | |
| benzoyl peroxide (topical) | 22.5% | ON | Generic | |
| tretinoin (topical) | 14.6% | ON | Generic | |
| sulfacetamide (topical) | 0.3% | NR | No-Generic | |
| erythromycin-benzoyl peroxide (topical) | 0.9% | OFF | No- Generic | |
| AZELEX (TOPICAL) | 1.4% | ON | Yes | |
| CLINAC BPO (TOPICAL) | 0.1% | ON | Yes | |
| NUOX (TOPICAL) | 0.0% | OFF | No | |
| RETIN-A MICRO (TOPICAL) | 7.6% | ON | Yes | |
| DIFFERIN (TOPICAL) | 3.2% | OFF | No | |
| ZACLIR (TOPICAL) | 0.0% | OFF | No | |
| CLINDAGEL (TOPICAL) | 0.0% | OFF | No | |
| BENZAMYCINPAK (TOPICAL) | 0.0% | OFF | No | |
| DUAC (TOPICAL) | 0.0% | OFF | No | |
| SULFOXYL (TOPICAL) | 0.0% | OFF | No | |

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications |
|--------------------------|--------------|--------------------|--------------------|-------------------------|
| AKNE-MYCIN (TOPICAL) | 0.5% | ON | No | |
| TAZORAC (TOPICAL) | 3.2% | ON | Yes | |
| BENZAFLIN (TOPICAL) | 2.4% | OFF | No | |
| NEOBENZ MICRO (TOPICAL) | 0.0% | OFF | No | |
| INOVA (TOPICAL) | 0.0% | OFF | No | |
| TRIAZ (TOPICAL) | 0.1% | OFF | No | |
| EVOCLIN (TOPICAL) | 0.2% | OFF | No | |
| CLINDAREACH (TOPICAL) | 0.0% | NR | No | |
| ZIANA (TOPICAL) | 0.0% | NR | No | |

- Dr Fleming made a motion to accept the recommendations as presented and Dr Sorkness seconded it.
- Votes— All in favor of the motion to accept the recommendations as presented.

Impetigo Agents, Topical Impetigo

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-------------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| mupirocin ointment (topical) | 76.8% | NR | Generic | | |
| ALTABAX (TOPICAL) | 0.1% | NR | No | | |
| BACTROBAN CREAM (TOPICAL) | 23.1% | NR | No | | |

- Dr Sorkness made a motion to accept the recommendations as presented and Dr Izard seconded it.
- This is a new class, and this is the first time it was reviewed by the PA Committee.
- Dr Izard asked about the application of these medications three times a day versus twice a day. There are no head-to-head trials indicating any superiority of any particular agent. Mupirocin is applied three times a day and has an indication for MRSA. Altabax is applied twice daily.
- Votes—All in favor of the motion to accept the recommendations as presented.

Analgesics, Narcotics Long Acting (Pain Control)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| methadone (oral) | 14.4% | ON | Generic | | |
| morphine er (oral) | 15.9% | ON | Generic | | |
| fentanyl (transderm.) | 28.3% | ON | Generic | | |
| KADIAN (ORAL) | 3.6% | ON | Yes | | |
| ULTRAM ER (ORAL) | 0.6% | OFF | No | | |
| OPANA ER (ORAL) | 0.1% | OFF | No | | |
| OXYCONTIN (ORAL) | 36.8% | OFF | No | | |
| AVINZA (ORAL) | 0.3% | OFF | No | | |

- Dr Fedderly made a motion to accept the recommendations as presented and Dr Fleming seconded it.

- The manufacturer of Oxycontin, Purdue, prevailed in the lawsuit preventing generic companies from manufacturing generic oxycodone ER. Oxycontin's patent now expires in 2011.
- Votes— All in favor of the motion to accept the recommendations as presented.

Analgesics, Narcotics Short Acting (Pain Control)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|--------------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| asa / codeine (oral) | 0.0% | ON | Generic | | |
| apap / codeine (oral) | 9.5% | ON | Generic | | |
| tramadol (oral) | 10.6% | ON | Generic | | |
| propoxyphene / apap (oral) | 10.8% | ON | Generic | | |
| hydrocodone / apap (oral) | 45.7% | ON | Generic | | |
| propoxyphene (oral) | 0.5% | ON | Generic | | |
| pentazocine / naloxone (oral) | 0.0% | OFF | No- Generic | | |
| morphine ir (oral) | 1.2% | ON | Generic | | |
| oxycodone ir (oral) | 6.6% | ON | Generic | | |
| oxycodone / apap (oral) | 13.2% | ON | Generic | | |
| hydromorphone (oral) | 0.6% | ON | Generic | | |
| hydrocodone / ibuprofen (oral) | 0.4% | ON | Generic | | |
| meperidine (oral) | 0.0% | OFF | No- Generic | | |
| codeine (oral) | 0.1% | ON | Generic | | |
| pentazocine / apap (oral) | 0.0% | OFF | No- Generic | | |
| tramadol / apap (oral) | 0.3% | OFF | No- Generic | | |
| oxycodone / asa (oral) | 0.1% | ON | Generic | | |
| dihydrocodeine/apap/caffeine (oral) | 0.0% | ON | Generic | | |
| butalbital compound w/codeine (oral) | 0.2% | ON | Generic | | |
| oxycodone / ibuprofen (oral) | 0.0% | NA | Generic | | |
| levorphanol (oral) | 0.0% | ON | Generic | | |
| fentanyl (buccal) | 0.0% | OFF | No- Generic | | |
| PANLOR DC (ORAL) | 0.0% | OFF | No | | |
| DARVON-N (ORAL) | 0.0% | OFF | No | | |
| OPANA (ORAL) | 0.0% | OFF | No | | |
| FENTORA (BUCCAL) | 0.0% | NR | No | | |

- Mr. Frazier made a motion to accept the recommendations as presented and Dr Fedderly seconded it.
- Votes— All in favor of the motion to accept the recommendations as presented.

Skeletal Muscle Relaxants (Spasticity and muscle relaxants)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| chlorzoxazone (oral) | 0.9% | NR | Generic | | |
| carisoprodol (oral) | 11.1% | NR | No-Generic | | |
| carisoprodol compound (oral) | 0.1% | NR | No-Generic | | |
| cyclobenzaprine (oral) | 44.5% | NR | Generic | | |
| methocarbamol (oral) | 3.6% | NR | Generic | | |
| tizanidine (oral) | 8.6% | NR | Generic | | |

| | | | | | |
|---------------------------------|-------|----|-------------------|--|--|
| baclofen (oral) | 21.7% | NR | Generic | | |
| orphenadrine (oral) | 2.3% | NR | No-Generic | | |
| orphenadrine compound (oral) | 0.2% | NR | No-Generic | | |
| dantrolene sodium (oral) | 1.5% | NR | Generic | | |
| SOMA (ORAL) | 0.0% | NR | No | | |
| SKELAXIN (ORAL) | 5.3% | NR | No | | |
| ZANAFLEX (ORAL) | 0.3% | NR | No | | |
| FEXMID (ORAL) | 0.0% | NR | No | | |
| AMRIX (ORAL) | 0.0% | NR | No | | |

- Dr Walker made a motion to accept the recommendations as presented and delay the implementation of the non-preferred status of carisoprodol and carisoprodol compound until 7/1/08. The State would send letters to the prescribers to notify them of the change. Mr. Gross seconded the motion.
- Dr Mergener discussed the Drug Effectives Review Project report that showed that carisoprodol and carisoprodol compound have a poor safety and efficacy profile due to the addiction and abuse potential.
- Votes-- All in favor of the motion to accept the recommendations as modified.

Angiotensin Modulators (High Blood Pressure)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|---------------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| enalapril / hctz (oral) | 11.7% | ON | Generic | | |
| captopril / hctz (oral) | 1.9% | ON | Generic | | |
| lisinopril / hctz (oral) | 42.7% | ON | Generic | | |
| benazepril / hctz (oral) | 4.4% | ON | Generic | | |
| fosinopril / hctz (oral) | 2.2% | ON | Generic | | |
| quinapril / hctz (oral) | 1.0% | OFF | No- Generic | | |
| moexipril / hctz (oral) | 0.1% | OFF | No- Generic | | |
| - New Generic – ramipril | | NR | NO | | |
| trandolapril (oral) | 0.3% | OFF | No- Generic | | |
| ACEON (ORAL) | 0.1% | OFF | No | | |
| BENICAR / BENICAR HCT (ORAL) | 2.6% | ON | Yes | | |
| AVAPRO / AVALIDE (ORAL) | 2.3% | ON | Yes | | |
| DIOVAN / DIOVAN HCT (ORAL) | 15.7% | ON | Yes | | |
| MICARDIS / MICARDIS HCT (ORAL) | 1.6% | ON | Yes | | |
| COZAAR / HYZAAR (ORAL) | 11.7% | ON | Yes | | |
| ALTACE (ORAL) | 1.2% | OFF | No | | |
| TEKTURNA (ORAL) | 0.0% | OFF | No | | |

| | | | | | |
|------------------------------------|------|-----|-----------|--|--|
| ATACAND / ATACAND HCT (ORAL) | 0.6% | OFF | No | | |
| TEVETEN / TEVETEN HCT (ORAL) | 0.0% | OFF | No | | |

- Dr Fedderly made a motion to accept the recommendations as presented and Dr Sorkness seconded it.
- Dr DeFranco stated that ARBs are similar in safety and efficacy.
- Votes— All in favor of the motion to accept the recommendations as presented.

Angiotensin Modulators/CCB Combinations (High Blood Pressure)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|---------------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| amlodipine / benazepril (oral) | 95.8% | ON | Generic | | |
| EXFORGE (ORAL) | 0.0% | NR | Yes | | |
| TARKA (ORAL) | 4.1% | ON | Yes | | |
| AZOR (ORAL) | 0.0% | NR | No | | |
| LEXXEL (ORAL) | 0.1% | OFF | No | | |

- Mr Frazier made a motion to accept the recommendations as presented and Dr Fleming seconded it.
- Dr Fedderly asked about the amlodipine/benazepril pricing. All of the generic agents for this drug are MAC'ed.
- Votes-- All in favor of the motion to accept the recommendations as presented

Anticoagulants, Injectable (Clot prevention)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| FRAGMIN (SUBCUTANE.) | 3.6% | ON | Yes | | |
| LOVENOX (SUBCUTANE.) | 93.1% | ON | Yes | | |
| ARIXTRA (SUBCUTANE.) | 3.0% | ON | Yes | | |
| INNOHEP (SUBCUTANE.) | 0.3% | OFF | No | | |

- Dr Fedderly made a motion to accept the recommendations as presented and Mr Frazier seconded it.
- Votes--All in favor of the motion to accept the recommendations as presented.

Beta-Blockers (High blood pressure and heart failure)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|---------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| atenolol (oral) | 34.4% | ON | Generic | | |
| pindolol (oral) | 0.1% | ON | Generic | | |
| metoprolol (oral) | 49.2% | ON | Generic | | |
| carvedilol (oral) | 6.6% | ON | Generic | | |
| nadolol (oral) | 1.1% | ON | Generic | | |
| sotalol (oral) | 1.1% | ON | Generic | | |
| acebutolol (oral) | 0.2% | ON | Generic | | |
| propranolol (oral) | 4.8% | ON | Generic | | |

| | | | | | |
|--------------------------|------|-----|----------------|--|--|
| labetalol (oral) | 1.6% | ON | Generic | | |
| timolol (oral) | 0.0% | ON | Generic | | |
| betaxolol (oral) | 0.1% | ON | Generic | | |
| bisoprolol (oral) | 0.5% | ON | Generic | | |
| LEVATOL (ORAL) | 0.0% | OFF | No | | |
| INNOPRAN XL (ORAL) | 0.0% | OFF | No | | |
| COREG CR (ORAL) | 0.1% | NR | No | | |

- Dr Fleming made a motion to accept the recommendations as presented and Mr Frazier seconded it.
- Dr Mergener discussed the DERP report which indicates that these agents are now being compared across classes. For example, a Beta Blocker is being compared to an ACE Inhibitor rather than to another Beta Blocker.
 - Dr Izard mentioned that Coreg CR was an issue, but there is no outstanding evidence to make it a preferred agent.
- Votes--All in favor of the motion to accept the recommendations as presented

Calcium Channel Blockers (High blood pressure)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| amlodipine (oral) | 48.7% | ON | Generic | | |
| nicardipine (oral) | 0.1% | ON | Generic | | |
| verapamil (oral) | 9.8% | ON | Generic | | |
| diltiazem (oral) | 24.9% | ON | Generic | | |
| nifedipine ir (oral) | 0.2% | ON | Generic | | |
| felodipine er (oral) | 3.0% | ON | Generic | | |
| nifedipine er (oral) | 10.3% | ON | Generic | | |
| isradipine (oral) | 0.0% | OFF | No- Generic | | |
| verapamil er pm (oral) | 0.1% | ON | Generic | | |
| nimodipine (oral) | 0.0% | ON | Generic | | |
| DYNACIRC CR (ORAL) | 0.3% | OFF | No | | |
| CARDIZEM LA (ORAL) | 1.1% | ON | Yes | | |
| COVERA-HS (ORAL) | 0.0% | OFF | No | | |
| SULAR (ORAL) | 1.4% | ON | No | | |
| CARDENE SR (ORAL) | 0.0% | OFF | No | | |

- Dr Fedderly made a motion to accept the recommendations as presented and Mr Frazier seconded it.
- Dr Mergener indicated that in the DERP report, CCB's were compared with ACE Inhibitors and had similar end points for congestive heart failure as amlodipine.
- Dr Fedderly asked why we are recommending including nimodipine. Dr. Mergener said that nimodipine had a special indication.
- Votes--All in favor of the motion to accept the recommendations as presented

Lipotropics, Other (Cholesterol lowering)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| gemfibrozil (oral) | 28.5% | ON | Generic | | |
| cholestyramine (oral) | 3.7% | ON | Generic | | |
| fenofibrate (oral) | 5.0% | ON | Generic | | |

| | | | | | |
|--------------------------|-------|-----|----------------|--|--|
| colestipol (oral) | 0.3% | ON | Generic | | |
| NIASPAN (ORAL) | 14.0% | ON | Yes | | |
| TRICOR (ORAL) | 11.8% | ON | Yes | | |
| ANTARA (ORAL) | 0.2% | OFF | No | | |
| LIPOFEN (ORAL) | 0.0% | NR | No | | |
| ZETIA (ORAL) | 34.5% | OFF | Yes | | |
| TRIGLIDE (ORAL) | 0.0% | OFF | No | | |
| WELCHOL (ORAL) | 1.0% | OFF | No | | |
| LOVAZA (ORAL) | 0.9% | OFF | No | | |

- Motion #1: Dr Walker made a motion to add Lovaza as a preferred agent. The motion did not have a second and therefore died.
- Motion #2: Dr Fedderly made a motion to accept the recommendations as presented and Mr Frazier seconded it.
 - Mr. Gross asked what the goal of the agents in this class was. Dr DeFranco responded that the goal is to reduce overall cardiovascular events. There is a tradeoff with net overall benefits.
- Votes-All in favor of the motion to accept the recommendations as presented

Lipotropics, Statins (Cholesterol Lowering)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|----------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| simvastatin (oral) | 43.1% | ON | Generic | | |
| pravastatin (oral) | 1.5% | ON | Generic | | |
| lovastatin (oral) | 17.2% | ON | Generic | | |
| LESCOL / LESCOL XL (ORAL) | 3.8% | ON | Yes | | |
| LIPITOR (ORAL) | 13.1% | ON | Yes | | |
| VYTORIN (ORAL) | 16.6% | ON | Yes | | |
| ADVICOR (ORAL) | 0.7% | ON | No | | |
| CRESTOR (ORAL) | 3.6% | OFF | No | | |
| CADUET (ORAL) | 0.3% | OFF | No | | |
| ALTOPREV (ORAL) | 0.1% | OFF | No | | |

- Dr Sorkness made a motion to accept the recommendations as presented and Dr Fedderly seconded it.
- Dr Mergener the DERP report. There were two new indications presented; one for Lipitor to prevent heart attack and stroke. Crestor received an indication for slowing the progression of plaque in the 40 mg strength.
 - Dr Walker asked Dr Mergener about equipotent doses and their impact. Dr Mergener responded that it is necessary when comparing these agents, to compare equipotent doses.
 - Dr IZARD expressed concerns about the continuing changing of preferred agents. There are no significant changes in this class.
- Votes- All in favor of the motion to accept the recommendations as presented. Dr DeFranco abstained from voting.

-

Otic Fluoroquinolones (Ear infections)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| ofloxacin (otic) | 41.4% | ON | Generic | | |
| CIPRO HC (OTIC) | 0.6% | OFF | No | | |
| CIPRODEX (OTIC) | 58.0% | ON | Yes | | |

- Dr Izard made a motion to accept the recommendations as presented and Mr. Gross seconded it.
- Votes--All in favor of the motion to accept the recommendations as presented

Antibiotics, GI (GI Infections)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| metronidazole (oral) | 89.2% | NR | Generic | | |
| neomycin (oral) | 2.7% | NR | Generic | | |
| TINDAMAX (ORAL) | 0.1% | NR | Yes | | |
| FLAGYL ER (ORAL) | 0.1% | NR | No | | |
| ALINIA (ORAL) | 0.2% | NR | Yes | | |
| VANCOCIN HCL (ORAL) | 3.9% | NR | Yes | | |
| XIFAXAN (ORAL) | 3.8% | NR | No | | |

- Dr Fleming made a motion to accept the recommendations as presented and Mr. Frazier seconded it.
- This is a new class for this review. The variety of preferred agents in this class has different mechanisms of action.
- Votes--All in favor of the motion to accept the recommendations as presented

Proton Pump Inhibitors (Ulcers and Reflux)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| omeprazole (oral) | 3.3% | OFF | No-Generic | | |
| PREVACID (ORAL) | 32.6% | ON | Yes | | |
| NEXIUM (ORAL) | 48.1% | ON | Yes | | |
| PRILOSEC OTC (ORAL) | 0.0% | NR | Yes | | |
| ZEGERID (ORAL) | 0.1% | OFF | No | | |
| ACIPHEX (ORAL) | 3.3% | OFF | No | | |
| PROTONIX (ORAL) | 7.8% | OFF | No | | |
| PREVACID SOLUTAB (ORAL) | 4.5% | ON | Yes | | |
| NEXIUM SUSPENSION (ORAL) | 0.0% | ON | YES | YES | |
| PREVACID SUSPENSION (ORAL) | 0.4% | ON | Yes | | |

- Mr Frazier made a motion to accept the recommendations as presented and Dr Fedderly seconded it.
- Dr Mergener discussed the DERP report and the non-erosive or empirically treated GERD. There is little evidence to support differences across products. Long-term studies were done for patients with GERD that evaluated Nexium and Prevacid's safety. No cardiovascular events were associated with long-term use.

- Votes- All in favor of the motion to accept the recommendations as presented.

Anticonvulsants (Seizure Disorders)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|---------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| phenobarbital (oral) | 2.5% | ON | Generic | | |
| clonazepam (oral) | 16.0% | ON | Generic | | |
| carbamazepine (oral) | 4.4% | ON | Generic | | |
| valproic acid (oral) | 1.6% | ON | Generic | | |
| gabapentin (oral) | 17.2% | ON | Generic | | |
| primidone (oral) | 1.5% | ON | Generic | | |
| phenytoin (oral) | 3.8% | ON | Generic | | |
| zonisamide (oral) | 1.2% | ON | Generic | | |
| mephobarbital (oral) | 0.0% | ON | Generic | | |
| ethosuximide (oral) | 0.2% | ON | Generic | | |
| oxcarbazepine (oral) | 3.9% | NA | Generic | | |
| lamotrigine (oral) | 0.3% | OFF | No- Generic | | |
| PHENYTEK (ORAL) | 0.1% | OFF | No | | |
| CELONTIN (ORAL) | 0.0% | ON | Yes | | |
| CARBATROL (ORAL) | 1.8% | ON | Yes | | |
| TEGRETOL XR (ORAL) | 1.4% | OFF | No | | |
| PEGANONE (ORAL) | 0.0% | ON | Yes | | |
| DEPAKOTE SPRINKLE (ORAL) | 2.3% | ON | Yes | | |
| DEPAKOTE (ORAL) | 6.4% | ON | Yes | | |
| GABITRIL (ORAL) | 0.3% | ON | Yes | | |
| EQUETRO (ORAL) | 0.0% | ON | Yes | | |
| FELBATOL (ORAL) | 0.8% | ON | Yes | | |
| DEPAKOTE ER (ORAL) | 6.6% | ON | Yes | | |
| LAMICTAL (ORAL) | 10.6% | ON | Yes | | |
| LYRICA (ORAL) | 4.0% | ON | Yes | | |
| TOPAMAX (ORAL) | 7.2% | ON | Yes | | |
| KEPPRA (ORAL) | 5.1% | ON | Yes | | |
| DIASTAT (RECTAL) | 0.7% | ON | Yes | | |

- Dr Izard made a motion to accept the recommendations as presented and Dr Boblin seconded it.
- Dr. Mergener presented the DERP report and discussed uses of these medications for off-label indications such as pain, fibromyalgia, and bipolar disease.
- Alicia Walker asked about grandfathering that had previously occurred.
- There was a reminder that members who transitioned from HMOS to BadgerCare Plus on 2/1/08 have a 60 day grace period before PA is required on 4/2/08.
- Lamictal is available as the preferred agent. Generic lamotrigine is non-preferred.
- Dr. Izard asked if diagnosis restrictions could be applied to Lyrica. Dr. Mergener indicated this is not likely and would most likely be dealt with DUR interventions.
- Dr. Sorkness recommended keeping Lamictal titration packs available for the first month following the release of the generic as mentioned by Dr Diamond.
- Votes— All in favor of the motion to accept the recommendations as presented. Dr Boblin abstained from voting.

Sedative Hypnotics (Insomnia and sleep disorders)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| temazepam (oral) | 24.0% | ON | Generic | | |
| flurazepam (oral) | 1.8% | ON | Generic | | |
| triazolam (oral) | 5.0% | ON | Generic | NP | |
| chloral hydrate (oral) | 0.8% | ON | Generic | | |
| zolpidem (oral) | 40.3% | ON | Generic | | |
| estazolam (oral) | 0.7% | ON | Generic | | |
| RESTORIL 7.5 MG (ORAL) | 0.1% | OFF | No | | |
| DORAL (ORAL) | 0.0% | OFF | No | | |
| ROZEREM (ORAL) | 4.2% | ON | Yes | | |
| LUNESTA (ORAL) | 12.4% | OFF | No | | |
| AMBIEN CR (ORAL) | 10.0% | OFF | No | | |
| SONATA (ORAL) | 0.7% | OFF | No | | |

- Dr. Boblin made a motion to make triazolam non-preferred the recommendations. Dr Sorkness seconded the motion.
- Mr. Gros asked if there might be a unique indication for triazolam. The response was no.
- Votes—All members were in favor of the motion.
- Second motion was made by Dr. Sorkness to accept the remaining recommendations. Dr. Boblin seconded the motion.
- Votes—All members were in favor of the motion.

Bladder Relaxant Preparations (Overactive Bladder)-

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|----------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| oxybutynin (oral) | 25.9% | ON | Generic | | |
| oxybutynin er (oral) | 27.9% | ON | Generic | | |
| OXYTROL (TRANSDERM.) | 2.6% | ON | Yes | | |
| SANCTURA (ORAL) | 3.1% | ON | Yes | | |
| VESICARE (ORAL) | 16.6% | ON | Yes | | |
| ENABLEX (ORAL) | 12.7% | ON | Yes | | |
| SANCTURA XR (ORAL) | 0.0% | NR | Yes | | |
| DETROL LA (ORAL) | 10.0% | OFF | Yes | | |
| DETROL (ORAL) | 1.2% | OFF | No | | |

- Dr Fleming made a motion to accept the recommendations as presented and Mr. Frazier seconded it.
- Votes-- All in favor of the motion to accept the recommendations as presented

BPH Treatments (Enlargement of the prostate)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|--------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| doxazosin (oral) | 29.0% | ON | Generic | | |
| terazosin (oral) | 16.1% | ON | Generic | | |
| finasteride (oral) | 5.7% | ON | Generic | | |
| UROXATRAL (ORAL) | 2.6% | ON | Yes | | |
| AVODART (ORAL) | 8.1% | ON | Yes | | |

| | | | | | |
|----------------------|-------|-----|------------|--|--|
| FLOMAX (ORAL) | 38.6% | ON | Yes | | |
| CARDURA XL (ORAL) | 0.0% | OFF | No | | |

- Dr Sorkness made a motion to accept the recommendations as presented and Dr Izard seconded it
- Votes-- All in favor of the motion to accept the recommendations as presented

Phosphate Binders (Removal of phosphate in kidney disease)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| PHOSLO (ORAL) | 35.9% | ON | Yes | | |
| RENAGEL (ORAL) | 56.9% | ON | Yes | | |
| FOSRENOL (ORAL) | 7.2% | ON | Yes | | |

- Mr Frazier made a motion to accept the recommendations as presented and Dr Fedderly seconded it.
- Votes-- All in favor of the motion to accept the recommendations as presented

Hepatitis C Agents (Viral Infection of the liver)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|---------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| ribavirin (oral) | 42.3% | ON | Generic | | |
| PEGASYS (SUBCUTANE.) | 34.2% | ON | Yes | | |
| PEG-INTRON REDIPEN (SUBCUTANE.) | 14.3% | ON | Yes | | |
| PEG-INTRON (SUBCUTANE.) | 2.6% | ON | Yes | | |
| INFERGEN (SUBCUTANE.) | 6.6% | OFF | No | | |

- Dr Fedderly made a motion to accept the recommendations as presented and Dr Fleming seconded it.
- Dr Mergener presented the DERP report and stated that the endpoints in the studies differ. They are looking at a number of different endpoints including SVR, response rates, genotypes and phenotypes. It is difficult to compare the drugs when the studies use different endpoints.
- Votes— All in favor of the motion to accept the recommendations as presented.

Multiple Sclerosis Agents (Multiple Sclerosis)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| COPAXONE (SUBCUTANE.) | 40.8% | ON | Yes | | |
| AVONEX (INTRAMUSC.) | 27.2% | ON | Yes | | |
| BETASERON (SUBCUTANE.) | 15.4% | ON | Yes | | |
| REBIF (SUBCUTANE.) | 16.6% | ON | Yes | | |

- Dr Sorkness made a motion to accept the recommendations as presented and Dr Fedderly seconded it.
- Votes-- All in favor of the motion to accept the recommendations as presented

Ulcerative Colitis Agents (Inflammation and sores of the intestine)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| sulfasalazine (oral) | 33.6% | ON | Generic | | |
| mesalamine (rectal) | 0.9% | ON | Generic | | |
| DIPENTUM (ORAL) | 0.3% | OFF | No | | |
| COLAZAL (ORAL) | 2.5% | ON | Yes | | |
| ASACOL (ORAL) | 54.0% | ON | Yes | | |
| PENTASA (ORAL) | 6.8% | OFF | No | | |
| CANASA (RECTAL) | 1.8% | ON | Yes | | |
| LIALDA (ORAL) | 0.1% | NR | No | | |

- Mr. Frazier made a motion to accept the recommendations as presented and Dr Boblin seconded it.
- Dr Walker asked if Asacol and Lialda were better than placebo. There are no head-to-head studies, only a small placebo controlled trial with 300 patients.
- Votes--All in favor of the motion to accept the recommendations as presented

Hypoglycemic, Meglitinides (Type 2 Diabetes)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| STARLIX (ORAL) | 74.8% | ON | Yes | | |
| PRANDIN (ORAL) | 25.2% | OFF | No | | |

- Dr Fleming made a motion to accept the recommendations as presented and Mr Frazier seconded it.
- Votes--All in favor of the motion to accept the recommendations as presented

Hypoglycemic, TZD (Diabetes, oral meds)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|----------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| AVANDARYL (ORAL) | 0.7% | ON | Yes | | |
| DUETACT (ORAL) | 0.0% | OFF | Yes | | |
| ACTOS (ORAL) | 55.8% | ON | Yes | | |
| AVANDIA (ORAL) | 38.7% | ON | Yes | | |
| AVANDAMET (ORAL) | 4.1% | ON | Yes | | |
| ACTOPLUS MET (ORAL) | 0.6% | OFF | Yes | | |

- Mr. Frazier made a motion to accept the recommendations as presented and Dr DeFranco seconded it.
- Votes-- All in favor of the motion to accept the recommendations as presented

Antihistamines, Minimally Sedating (Allergies)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|---|--------------|--------------------|--------------------|-------------------------|-------------------------|
| loratadine / loratadine-d (oral) | 59.1% | ON | Generic | | |
| fexofenadine (oral) | 11.4% | OFF | No- Generic | | |

| | | | | | |
|--------------------------|-------|-----|----|--|--|
| SEMPREX-D (ORAL) | 0.0% | OFF | No | | |
| CLARITIN CHEW OTC (ORAL) | 0.0% | OFF | No | | |
| ALLEGRA SYRUP (ORAL) | 0.1% | NR | No | | |
| CLARINEX SYRUP (ORAL) | 0.1% | OFF | No | | |
| ZYRTEC SYRUP (ORAL) | 6.1% | OFF | No | | |
| XYZAL (ORAL) | 0.0% | NR | No | | |
| ZYRTEC / ZYRTEC-D (ORAL) | 21.1% | OFF | No | | |
| ALLEGRA-D 12 HOUR (ORAL) | 2.1% | OFF | No | | |

- Dr Fedderly made a motion to accept the recommendations as presented and Dr Sorkness seconded it.
- Since generic Zyrtec, cetirizine 5 and 10 mg tablets are available, they will be added as covered on 3/1/08. As other generic cetirizine products become available, they will be evaluated for coverage.
- Dr Fedderly asked about SeniorCare and coverage of the OTC products. The cost of the OTCs is close to the brand name copay for the other drugs in this class.
- Votes--All in favor of the motion to accept the recommendations as presented

Antimigraine Agents, Triptans (Migraine Headaches)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|-----------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| RELPAX (ORAL) | 3.1% | OFF | Yes | | |
| IMITREX (NASAL) | 4.0% | ON | Yes | | |
| FROVA (ORAL) | 0.8% | OFF | No | | |
| AMERGE (ORAL) | 2.9% | ON | No | | |
| IMITREX (ORAL) | 52.6% | ON | Yes | | |
| MAXALT / MAXALT MLT (ORAL) | 17.3% | ON | Yes | | |
| IMITREX (SUBCUTANE.) | 9.7% | ON | Yes | | |
| AXERT (ORAL) | 6.8% | ON | No | | |
| ZOMIG / ZOMIG ZMT (ORAL) | 2.8% | OFF | No | | |
| ZOMIG (NASAL) | 0.2% | OFF | No | | |

- Dr Izard made a motion to accept the recommendations as presented and Dr Fedderly seconded it.
- Votes— All in favor of the motion to accept the recommendations as presented

Erythropoiesis Stimulating Proteins (Treatment of low blood levels)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|----------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| ARANESP (INJECTION) | 34.4% | ON | Yes | | |
| PROCRIT (INJECTION) | 64.5% | ON | Yes | | |
| EPOGEN (INJECTION) | 1.1% | OFF | No | | |

- Mr. Maike made a motion to accept the recommendations as presented and Mr. Gross seconded it.
- Votes-- All in favor of the motion to accept the recommendations as presented

Growth Hormone (Growth deficiencies)

| Brand Name | Market Share | Current PDL Status | PDL Recommendation | Committee Modifications | Secretary Modifications |
|--------------------------------|--------------|--------------------|--------------------|-------------------------|-------------------------|
| OMNITROPE (INJECTION) | 0.0% | NR | No | | |
| TEV-TROPIN (INJECTION) | 3.5% | ON | Yes | | |
| NUTROPIN (INJECTION) | 4.3% | OFF | Yes | | |
| NUTROPIN AQ (INJECTION) | 57.5% | ON | Yes | | |
| SAIZEN (INJECTION) | 5.3% | ON | Yes | | |
| NORDITROPIN (INJECTION) | 23.5% | OFF | No | | |
| SEROSTIM (INJECTION) | 0.0% | OFF | No | | |
| GENOTROPIN (INJECTION) | 3.4% | ON | Yes | | |
| HUMATROPE (INJECTION) | 1.4% | OFF | No | | |
| ZORBTIVE (INJECTION) | 1.1% | OFF | No | | |

- Mr Frazier made a motion to accept the recommendations as presented and also to grandfather the managed care members taking Norditropin who transitioned to BadgerCare Plus. Dr Fedderly seconded the motion.
- Votes-- All in favor of the motion to accept the recommendations as presented

Mr. Helgerson thanked Tom Frazier for his service to the committee and thanked the entire committee for their service as well.

The Mental Health Drug Advisors meeting is scheduled for March 4, 2008 from 9-11:30 am at 1 W Wilson Street in room 751.

The next PA Committee meeting is scheduled for August 13, 2008.

Mr. Frazier made a motion to adjourn the meeting and Dr Fedderly seconded the motion. All members were in favor of the motion. Mr. Helgerson adjourned the meeting at 3:30 pm.